Inactive

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) toestablish an eff ective, eff icient, integrated pharmacy benefits program for theMilitary Health System (MHS) which includes th... The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) toestablish an eff ective, eff icient, integrated pharmacy benefits program for theMilitary Health System (MHS) which includes the purchase pharmaceuticalagents. The law and implementing regulation (32 CFR Section 199.21) describethe process by which the DoD Pharmacy and Therapeutics (P&T) Committee willconsider the relative clinical eff ectiveness and relative cost eff ectiveness ofpharmaceutical agents in a therapeutic class in recommending the selection ofagents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, theclassification of a pharmaceutical agent as generic, formulary, Basic CoreFormulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior tothe scheduled P&T Committee meeting, a Request for Quotation (RFQ) forpharmaceutical agents within Drug Classes identified for placement on the UFhas been issued to obtain quotes from industry. The Defense Health Agency mayaward Uniform Formulary Blanket Purchase Agreements (UF BPA) and theUniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: November 2023: The following drug classes/subclass will be reviewed: a. Migraine Agents – Subclass: CGRP Cluster Headache Emgality 100 mg/1ml b. Migraine Agents – Subclass: CGRP Preventative Aimovig Ajovy Emgality 120 mg c. Neurological Agents Miscellaneous – Subclass: Movement Disorders Austedo Austedo XR Ingrezza The RFQ, including UF BPA and UF ADP appendices are attached herein. The instructions, important deadlines, and points of contact are in document, RFQHT9402-23-Q-9401. Pre-proposal teleconference is on August 9, 2023, details are stated in Part 2.5. Pre-proposal teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.